NCCN Guidelines to Be Integrated Into OpenEvidence's Medical AI Platform
The National Comprehensive Cancer Network (NCCN) has entered into a licensing agreement with OpenEvidence that would make the NCCN Clinical Practice Guidelines in Oncology accessible through OpenEvidence's AI–powered medical platform.
“This collaboration will help clinicians access trusted recommendations in a way that harnesses the evolving power of artificial intelligence to support learning and care delivery in cancer, grounded in source documentation and references,” said Crystal S. Denlinger, MD, FACP, Chief Executive Officer of NCCN. “NCCN works to advance quality, effective, equitable, and accessible cancer care and prevention so that all people can live better lives. Health information technology organizations like OpenEvidence can play a key role in connecting providers with leading evidence- and expert consensus-based recommendations on cancer care and prevention.”
As a part of the agreement, the NCCN Guidelines and related content from JNCCN—Journal of the National Comprehensive Cancer Network will be integrated into OpenEvidence's large language model platform for medical searches and clinical decision-making support. This will enable diagnostic and treatment recommendations to be found through natural language searches, so that clinicians can find the information they need faster and still be assured of the quality and basis for these recommendations. Hundreds of thousands of U.S. physicians are already using OpenEvidence daily for quick access to clinical information and answers to medical questions.
“NCCN guidelines are the gold standard for oncology practice around the world,” said Daniel Nadler, PhD, Chief Executive Officer of OpenEvidence. “We are honored to work hand-in-hand with NCCN to make this information more accessible in real time, across every clinical setting, through a secure and responsible application of AI. This collaboration represents a major leap toward making expert medical knowledge universally available and actionable.”
OpenEvidence is the fastest-growing clinical decision support platform in the United States and contains information in partnership with The New England Journal of Medicine, JAMA and the JAMA Network specialty journals, and the Mayo Clinic Platform Accelerate program, as well as from society partners, including the American Diabetes Association, the American Academy of Orthopaedic Surgeons, and more. All NCCN information published on OpenEvidence will strictly adhere to the NCCN's evidence and quality control review and will link to source documentation.
ASCO AI in Oncology is published by Conexiant under a license arrangement with the American Society of Clinical Oncology, Inc. (ASCO®). The ideas and opinions expressed in ASCO AI in Oncology do not necessarily reflect those of Conexiant or ASCO. For more information, see Policies.
Performance of a convolutional neural network in determining differentiation levels of cutaneous squamous cell carcinomas was on par with that of experienced dermatologists, according to the results of a recent study published in JAAD International.
“This type of cancer, which is a result of mutations of the most common cell type in the top layer of the skin, is strongly linked to accumulated [ultraviolet] radiation over time. It develops in sun-exposed areas, often on skin already showing signs of sun damage, with rough scaly patches, uneven pigmentation, and decreased elasticity,” stated lead researcher Sam Polesie, MD, PhD, Associate Professor of Dermatology and Venereology at the University of Gothenburg and Practicing Dermatologist at Sahlgrenska University Hospital, both in Gothenburg, Sweden.